Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
IONS•Phase 3 fusion study results
Sept. 22 (Reuters) - Ionis Pharmaceuticals, Inc. (NYSE: IONS):
- Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen, marking a significant milestone in advancing first potential disease modifying treatment for FUS-ALS.
- Ulefnersen demonstrates statistically significant improvement on primary endpoint in FUS-ALS.
- Ulefnersen demonstrates favorable safety and tolerability profile.
